Ocular Therapeutix Inc (NASDAQ: OCUL) on Tuesday, soared 3.23% from the previous trading day, before settling in for the closing price of $9.61. Within the past 52 weeks, OCUL’s price has moved between $5.78 and $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 8.51%. The company achieved an average annual earnings per share of -17.19%. With a float of $133.28 million, this company’s outstanding shares have now reached $159.26 million.
The extent of productivity of a business whose workforce counts for 274 workers is very important to gauge. In terms of profitability, gross margin is 90.66%, operating margin of -342.52%, and the pretax margin is -323.44%.
Ocular Therapeutix Inc (OCUL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ocular Therapeutix Inc is 16.33%, while institutional ownership is 74.32%. The most recent insider transaction that took place on Jun 02 ’25, was worth 111,581. In this transaction Chief Medical Officer of this company sold 13,861 shares at a rate of $8.05, taking the stock ownership to the 206,805 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Officer proposed sale 13,861 for $8.05, making the entire transaction worth $111,524.
Ocular Therapeutix Inc (OCUL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -17.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.11% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Ocular Therapeutix Inc (OCUL) is currently performing well based on its current performance indicators. A quick ratio of 10.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
The latest stats from [Ocular Therapeutix Inc, OCUL] show that its last 5-days average volume of 2.03 million was superior to 1.71 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 78.62%.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 94.30%, which indicates a significant increase from 88.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.50 in the past 14 days, which was lower than the 0.51 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.24, while its 200-day Moving Average is $8.49. Now, the first resistance to watch is $10.15. This is followed by the second major resistance level at $10.39. The third major resistance level sits at $10.61. If the price goes on to break the first support level at $9.70, it is likely to go to the next support level at $9.48. Assuming the price breaks the second support level, the third support level stands at $9.24.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
Market capitalization of the company is 1.58 billion based on 159,300K outstanding shares. Right now, sales total 63,720 K and income totals -193,510 K. The company made 10,700 K in profit during its latest quarter, and -64,050 K in sales during its previous quarter.
